L
Lori Shafner
Researcher at Alexion Pharmaceuticals
Publications - 11
Citations - 535
Lori Shafner is an academic researcher from Alexion Pharmaceuticals. The author has contributed to research in topics: Paroxysmal nocturnal hemoglobinuria & Eculizumab. The author has an hindex of 6, co-authored 11 publications receiving 324 citations.
Papers
More filters
Journal ArticleDOI
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Jong Wook Lee,Flore Sicre de Fontbrune,Lily Wong Lee Lee,Viviani Pessoa,Sandra Fátima Menosi Gualandro,Wolfgang Füreder,Vadim Ptushkin,Scott T. Rottinghaus,Lori Volles,Lori Shafner,Rasha Aguzzi,Rajendra Pradhan,Hubert Schrezenmeier,Hubert Schrezenmeier,Anita J. Hill +14 more
TL;DR: In conclusion, ravulizumab given every 8 weeks achieved noninferiority compared with eculizumAB given every 2 weeks for all efficacy end points, with a similar safety profile.
Journal ArticleDOI
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Austin G. Kulasekararaj,Anita J. Hill,Scott T. Rottinghaus,Saskia Langemeijer,Richard A. Wells,F. Ataulfo Gonzalez-Fernandez,Anna Gaya,Jong Wook Lee,Emilio Ojeda Gutierrez,Caroline I. Piatek,Jeff Szer,Antonio M. Risitano,Shinji Nakao,Eric Bachman,Lori Shafner,Andrew I. Damokosh,Stephan Ortiz,Alexander Röth,Régis Peffault de Latour +18 more
TL;DR: Patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered every 2 weeks to ravulizumabs administered every 8 weeks, and no meningococcal infections or discontinuations due to adverse events occurred.
Journal ArticleDOI
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Alexander Röth,Scott T. Rottinghaus,Anita J. Hill,Eric Bachman,Jin Seok Kim,Hubert Schrezenmeier,Hubert Schrezenmeier,Louis Terriou,Alvaro Urbano-Ispizua,Richard A. Wells,Jun Ho Jang,Austin G. Kulasekararaj,Jeff Szer,Rasha Aguzzi,Andrew I. Damokosh,Lori Shafner,Jong Wook Lee +16 more
TL;DR: Ravulizumab provided rapid and sustained reduction in complement-mediated hemolysis and improved QoL at dosing intervals up to 12 weeks and improved quality of life (QoL) measures in all cohorts.
Journal ArticleDOI
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky,Régis Peffault de Latour,Scott T. Rottinghaus,Alexander Röth,Antonio M. Risitano,Ilene C. Weitz,Peter Hillmen,Jaroslaw P. Maciejewski,Jeff Szer,Jong Wook Lee,Austin G. Kulasekararaj,Lori Volles,Andrew I. Damokosh,Stephan Ortiz,Lori Shafner,Peng Liu,Anita Hill,Hubert Schrezenmeier +17 more
TL;DR: The results suggest that the immediate, complete, and sustained C5 inhibition achieved through weight-based dosing of ravulizumab reduces the risk of BTH by eliminating BTH associated with suboptimal C4 inhibition in patients with PNH.
Journal ArticleDOI
Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study
Jong Wook Lee,Eric Bachman,Rasha Aguzzi,Jun Ho Jang,Jin Seok Kim,Scott T. Rottinghaus,Lori Shafner,Jeff Szer +7 more
TL;DR: The primary efficacy outcome was change in complement-mediated hemolysis as measured by LDH level, and other endpoints included changes in hematologic parameters, blood transfusions, FACIT-Fatigue scores, and pharmacokinetic parameters.